Skip to main content

Table 4 Analysis of success rate of post-pyloric placement of the nasojejunal tube in prespecified subgroups

From: Metoclopramide or domperidone improves post-pyloric placement of spiral nasojejunal tubes in critically ill patients: a prospective, multicenter, open-label, randomized, controlled clinical trial

Subgroup

Metoclopramide group ( n = 100)

Domperidone group ( n = 99)

Control group ( n = 99)

Total ( n = 298)

P value

Age

     

<60 years

22/38 (57.9)*

19/35 (54.3)*

11/41 (26.8)

52/114 (45.6)

0.0100

≥60 years

33/62 (53.2)*

32/64 (50.0)*

16/58 (27.6)

81/184 (44.0)

0.0090

Sex

     

 Male

38/67 (56.7)**

28/58 (48.3)*

17/72 (23.6)

83/197 (42.1)

0.0002

 Female

17/33 (51.5)

23/41 (56.1)

10/27 (37.0)

50/101 (49.5)

0.2944

APACHE II score

     

  < 20

31/45 (68.9)**

27/43 (62.8)*

14/43 (32.6)

72/131 (55.0)#

0.0013

  ≥ 20

24/55 (43.6)

24/56 (42.9)

13/56 (23.8)

61/167 (36.5)

0.0398

SOFA score

     

  < 12

39/66 (59.1)*

37/68 (54.4)‡

24/66 (36.4)

100/200 (50.0)†

0.0221

  ≥ 12

16/34 (47.1)**

14/31 (45.2)**

3/33 (9.1)

33/98 (33.7)

0.0012

Neurological diseases

     

 Yes

27/48 (56.3)**

19/41 (46.3)∫

9/39 (23.1)

55/128 (43.0)

0.0069

 No

28/52 (53.8)*

32/58 (55.2)*

18/60 (30.0)

78/170 (45.9)

0.0089

Sepsis

     

 Yes

9/14 (64.3)*

7/11 (63.6)*

2/13 (15.4)

18/38 (47.4)

0.0173

 No

46/86 (53.5)**

44/88 (50.0)*

25/86 (29.1)

115/260 (44.2)

0.0023

Use of sedatives or analgesics

     

 Yes

15/35 (42.9)

16/37 (43.2)

12/38 (31.6)

43/110 (39.1)

0.5023

 No

40/65 (61.5)**

35/62 (56.5)**

15/61 (24.6)

90/188 (47.9)

0.0001

Use of vasopressors

     

 Yes

10/24 (41.7)

8/21 (38.1)

4/25 (16.0)

22/70 (31.4)¶

0.1129

 No

45/76 (59.2)**

43/78 (55.1)**

23/74 (31.1)

111/228 (48.7)

0.0009

Mechanical ventilation

     

 Yes

33/72 (45.8)

31/66 (47.0)

19/68 (27.9)

83/206 (40.3)‖

0.0397

 No

22/28 (78.6)**

20/33 (60.6)*

8/31 (25.8)

50/92 (54.3)

0.0002

  1. Data presented as success/total (%). APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment. *P <0.016, metoclopramide or domperidone group versus controls. **P <0.0033, metoclopramide or domperidone group versus controls. # P = 0.0015, APACHE II score <20 versus ≥20. ‡ P = 0.0360, SOFA <12 in the domperidone group versus controls. † P = 0.0077, SOFA score <12 versus ≥12. ∫ P = 0.0292, neurologic diseases in the domperidone group versus controls. ¶ P = 0.0111, use of vasopressors versus without vasopressor. ‖ P = 0.0241, mechanical ventilation versus no ventilation.